- A randomized study in 39 older adults reported an acute improvement in a mitochondrial energetic measure.
- MMPOWER-3 was a phase 3 randomized placebo-controlled trial in primary mitochondrial myopathy.
RESEARCH REBEL • EVIDENCE DOSSIER
Elamipretide / SS-31
HUMAN RANDOMIZED TRIALSA mitochondria-targeting tetrapeptide studied in randomized human trials. Outcomes vary by population and endpoint.
- Generalizability to healthy optimization use.
- Whether community protocols reproduce clinical exposure or outcomes.
PUBLISHED PROTOCOL EVIDENCE
Study parameter ≠ universal protocol.
Clinical-trial amounts, routes and durations are displayed only as study parameters attached to the original trial.
Numerical study entries carry:PopulationRouteFormulationAmountFrequencyDurationEndpointSource
COMMUNITY EVIDENCE
Document it. Don't upgrade it.
Community reports often focus on energy and exercise recovery; these are subjective and should include concurrent interventions.
Reported amount/rangeRouteFrequencyDurationGoalReported positivesReported negativesConcurrent compoundsSource + N
COMMUNITY-REPORTED • NOT CLINICALLY VALIDATED